LabGenius Therapeutics

Transforming the treatment of disease with a wholly-owned pipeline of highly selective therapeutic antibodies.

The EVA platform is a modality-agnostic discovery engine that integrates ML, high-throughput automation, and functional screening to deliver antibody therapeutics in under six weeks.

LabGenius’ presentation will debut the pre-clinical in vivo efficacy and tolerability data for their lead asset, a tumour selective bispecific T-cell engager.

LabGenius Therapeutics entered into a multi-year research collaboration, option, and licensing agreement to use its AI/ML-driven EVA platform to design and engineer multispecifics with enhanced therapeutic properties.

The company lists current job opportunities on its jobs board.

LabGenius Therapeutics collaborates with pharmaceutical partners on complex antibody constructs across a broad range of indications. Its EVA platform combines high-throughput experimentation and machine learning to identify designs not accessible through traditional methods.

LabGenius Therapeutics has a London headquarters for partnership, investment, and media enquiries. The company combines human and machine intelligence to advance antibody therapeutics.

LabGenius Therapeutics is pioneering a closed-loop platform that combines AI, robotic automation, and synthetic biology to accelerate the discovery of next-generation therapeutic antibodies for solid tumours.

The terms of use describe the conditions for accessing, browsing, and registering to use the LabGenius Therapeutics website.

LabGenius Therapeutics and LG Chem enter a research collaboration, option and license agreement focused on tumor-targeting multispecific antibodies. The multi-year collaboration will use EVA to design and engineer these antibodies.

Jun 2026 · LabGenius TherapeuticsNews article

LabGenius Therapeutics announces a scientific poster presentation at the 2026 AACR Annual Meeting. The announcement provides no further details about the poster.

Mar 2026 · LabGenius TherapeuticsNews article

LabGenius Therapeutics announces a new antibody optimization collaboration with Sanofi. The collaboration applies EVA to optimize therapeutic NANOBODY proteins for multiple targets.

Dec 2025 · LabGenius TherapeuticsNews article

LabGenius Therapeutics appoints Dr. Angus Sinclair as chief scientific officer, placing him in charge of the company's discovery and preclinical development efforts. The announcement does not describe specific programs, Sinclair's prior experience, or the timing of the appointment.

May 2025 · LabGenius TherapeuticsNews article